330 related articles for article (PubMed ID: 11942962)
1. The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours.
Spermon JR; De Geus-Oei LF; Kiemeney LA; Witjes JA; Oyen WJ
BJU Int; 2002 Apr; 89(6):549-56. PubMed ID: 11942962
[TBL] [Abstract][Full Text] [Related]
2. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma.
Kollmannsberger C; Oechsle K; Dohmen BM; Pfannenberg A; Bares R; Claussen CD; Kanz L; Bokemeyer C
Cancer; 2002 May; 94(9):2353-62. PubMed ID: 12015760
[TBL] [Abstract][Full Text] [Related]
3. [Positron emission tomography with [18 F]-2-fluoro-2-deoxy-D-glucose (18FDG-PET) in diagnosis of retroperitoneal lymph node metastases of testicular tumors].
Müller-Mattheis V; Reinhardt M; Gerharz CD; Fürst G; Vosberg H; Müller-Gärtner HW; Ackermann R
Urologe A; 1998 Nov; 37(6):609-20. PubMed ID: 9887489
[TBL] [Abstract][Full Text] [Related]
4. 18F-fluoro-2-deoxyglucose-positron emission tomography in the evaluation of nonseminomatous germ cell tumours at relapse.
Sanchez D; Zudaire JJ; Fernandez JM; Lopez J; Arocena J; Sanz G; Gimenez M; Rosell D; Robles JE; Berian JM
BJU Int; 2002 Jun; 89(9):912-6. PubMed ID: 12010239
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic value of 18F-FDG positron emission tomography for detection and treatment control of malignant germ cell tumors.
Tsatalpas P; Beuthien-Baumann B; Kropp J; Manseck A; Tiepolt C; Hakenberg OW; Burchert W; Franke WG; Wirth MP
Urol Int; 2002; 68(3):157-63. PubMed ID: 11919460
[TBL] [Abstract][Full Text] [Related]
6. Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours.
Lassen U; Daugaard G; Eigtved A; Højgaard L; Damgaard K; Rørth M
Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):396-402. PubMed ID: 12634968
[TBL] [Abstract][Full Text] [Related]
7. Positron emission tomography in the clinical staging of patients with Stage I and II testicular germ cell tumors.
Albers P; Bender H; Yilmaz H; Schoeneich G; Biersack HJ; Mueller SC
Urology; 1999 Apr; 53(4):808-11. PubMed ID: 10197862
[TBL] [Abstract][Full Text] [Related]
8. Use of fluorodeoxyglucose positron emission tomography scans in patients with advanced germ cell tumour following chemotherapy: single-centre experience with long-term follow up.
Karapetis CS; Strickland AH; Yip D; Steer C; Harper PG
Intern Med J; 2003; 33(9-10):427-35. PubMed ID: 14511195
[TBL] [Abstract][Full Text] [Related]
9. [18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group.
Oechsle K; Hartmann M; Brenner W; Venz S; Weissbach L; Franzius C; Kliesch S; Mueller S; Krege S; Heicappell R; Bares R; Bokemeyer C; de Wit M;
J Clin Oncol; 2008 Dec; 26(36):5930-5. PubMed ID: 19018083
[TBL] [Abstract][Full Text] [Related]
10. [18F]-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trial.
de Wit M; Brenner W; Hartmann M; Kotzerke J; Hellwig D; Lehmann J; Franzius C; Kliesch S; Schlemmer M; Tatsch K; Heicappell R; Geworski L; Amthauer H; Dohmen BM; Schirrmeister H; Cremerius U; Bokemeyer C; Bares R
Ann Oncol; 2008 Sep; 19(9):1619-23. PubMed ID: 18453520
[TBL] [Abstract][Full Text] [Related]
11. Fluorodeoxyglucose PET in the initial staging of germ cell tumours.
Hain SF; O'Doherty MJ; Timothy AR; Leslie MD; Partridge SE; Huddart RA
Eur J Nucl Med; 2000 May; 27(5):590-4. PubMed ID: 10853816
[TBL] [Abstract][Full Text] [Related]
12. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse.
Hain SF; O'Doherty MJ; Timothy AR; Leslie MD; Harper PG; Huddart RA
Br J Cancer; 2000 Oct; 83(7):863-9. PubMed ID: 10970686
[TBL] [Abstract][Full Text] [Related]
13. Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer?--Results of a study in 50 patients.
Cremerius U; Wildberger JE; Borchers H; Zimny M; Jakse G; Günther RW; Buell U
Urology; 1999 Nov; 54(5):900-4. PubMed ID: 10565755
[TBL] [Abstract][Full Text] [Related]
14. Role of
Dolci C; Ceppi L; Guerra L; Crivellaro C; Lamanna M; Adorni M; Elisei F; Bonazzi CM; Sina F; Fruscio R; Messa C
Int J Gynecol Cancer; 2019 Oct; 29(8):1298-1303. PubMed ID: 31366569
[TBL] [Abstract][Full Text] [Related]
15. FDG PET for detection and therapy control of metastatic germ cell tumor.
Cremerius U; Effert PJ; Adam G; Sabri O; Zimmy M; Wagenknecht G; Jakse G; Buell U
J Nucl Med; 1998 May; 39(5):815-22. PubMed ID: 9591582
[TBL] [Abstract][Full Text] [Related]
16. [Early prediction of treatment response to high-dose chemotherapy in patients with relapsed germ cell tumors using [18F]FDG-PET, CT or MRI, and tumor marker].
Pfannenberg AC; Oechsle K; Kollmannsberger C; Dohmen BM; Bokemeyer C; Bares R; Vontheim R; Claussen CD
Rofo; 2004 Jan; 176(1):76-84. PubMed ID: 14712410
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic accuracy of integrated (18)F-FDG PET/CT for restaging patients with malignant germ cell tumours.
Sharma P; Jain TK; Parida GK; Karunanithi S; Patel C; Sharma A; Thulkar S; Julka PK; Bal C; Kumar R
Br J Radiol; 2014 Aug; 87(1040):20140263. PubMed ID: 24896199
[TBL] [Abstract][Full Text] [Related]
18. Germ cell tumor: differentiation of viable tumor, mature teratoma, and necrotic tissue with FDG PET and kinetic modeling.
Sugawara Y; Zasadny KR; Grossman HB; Francis IR; Clarke MF; Wahl RL
Radiology; 1999 Apr; 211(1):249-56. PubMed ID: 10189480
[TBL] [Abstract][Full Text] [Related]
19. [Fluorodeoxyglucose (FDO) positron emission tomography (PET) in testicular germ cell tumors in adults: preliminary French clinical evaluation, development of the technique and its clinical applications].
Maszelin P; Lumbroso J; Theodore C; Foehrenbach H; Merlet P; Syrota A
Prog Urol; 2000 Dec; 10(6):1190-9. PubMed ID: 11217558
[TBL] [Abstract][Full Text] [Related]
20. Initial surveillance in men with marker negative clinical stage IIA non-seminomatous germ cell tumours.
Gerdtsson A; Negaard HFS; Almås B; Bergdahl AG; Cohn-Cedermark G; Glimelius I; Halvorsen D; Haugnes HS; Hedlund A; Hellström M; Holmberg G; Karlsdóttir Á; Kjellman A; Larsen SM; Thor A; Wahlqvist R; Ståhl O; Tandstad T
BJU Int; 2024 Jun; 133(6):717-724. PubMed ID: 38293778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
